Accessibility Menu
 
CytoMed Therapeutics logo

CytoMed Therapeutics

(NASDAQ) GDTC

Current Price$0.98
Market Cap$11.80M
Since IPO (2023)-75%
5 YearN/A
1 Year-58%
1 Month-0%

CytoMed Therapeutics Financials at a Glance

Market Cap

$11.80M

Revenue (TTM)

$388.79K

Net Income (TTM)

$4.14M

EPS (TTM)

$-0.26

P/E Ratio

-3.82

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.98

Volume

100

Open

$0.98

Previous Close

$0.98

Daily Range

$0.98 - $0.98

52-Week Range

$0.73 - $3.68

GDTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CytoMed Therapeutics

Industry

Biotechnology

Employees

42

CEO

Wee Kiat Tan, PhD

Headquarters

Singapore, 149544, SG

GDTC Financials

Key Financial Metrics (TTM)

Gross Margin

-38%

Operating Margin

-10%

Net Income Margin

-11%

Return on Equity

-52%

Return on Capital

-56%

Return on Assets

-52%

Earnings Yield

-26.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.80M

Shares Outstanding

11.83M

Volume

100

Avg. Volume

562.58K

Financials (TTM)

Gross Profit

$689.55K

Operating Income

$3.52M

EBITDA

$3.34M

Operating Cash Flow

$3.70M

Capital Expenditure

$703.13K

Free Cash Flow

$4.40M

Cash & ST Invst.

$2.10M

Total Debt

$482.56K

CytoMed Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$130.63K

+20.3%

Gross Profit

$432.18K

-543.7%

Gross Margin

-3.31%

N/A

Market Cap

$11.80M

N/A

Market Cap/Employee

$274.36K

N/A

Employees

43

N/A

Net Income

$1.35M

-142.3%

EBITDA

$1.73M

-237.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$1.61M

-54.0%

Accounts Receivable

$132.05K

+803.6%

Inventory

$0.00

-100.0%

Long Term Debt

$422.12K

+30.0%

Short Term Debt

$60.45K

+69.2%

Return on Assets

-51.86%

N/A

Return on Invested Capital

-55.77%

N/A

Free Cash Flow

$1.83M

-129.6%

Operating Cash Flow

$1.59M

-163.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NCNANuCana plc
$2.13+4.41%
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
PASGPassage Bio, Inc.
$5.11-4.49%
CLGNCollPlant Biotechnologies Ltd.
$0.38+2.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$16.10+0.04%
AAPLApple
$271.35+0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.63+0.10%
MARAMara Holdings
$11.99+0.12%

Questions About GDTC

What is the current price of CytoMed Therapeutics?

CytoMed Therapeutics is trading at $0.98 per share.

What is the 52-week range for CytoMed Therapeutics?

Over the past 52 weeks, CytoMed Therapeutics has traded between $0.73 and $3.68.

How much debt does CytoMed Therapeutics have?

As of the most recent reporting period, CytoMed Therapeutics reported total debt of $375,242.613.

How much cash does CytoMed Therapeutics have on hand?

CytoMed Therapeutics reported $1.63M in cash and cash equivalents in its most recent financial results.

What is CytoMed Therapeutics’s dividend yield?

CytoMed Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.